Thomas Carmody, PhD

Augmentation with aripiprazole, but not rTMS, improved quality of life significantly versus venlafaxine XR/duloxetine switch in patients with treatment-resistant depression.

Improvement in depression accounted for approximately 25% of the treatment effect of naltrexone-bupropion on methamphetamine treatment response.

Three patient-reported outcomes—Patient Health Questionnaire for Adolescents, Quick Inventory of Depressive Symptomatology–Self-Report, and Very Quick Inventory of Depressive Symptomatology–Self-Report—can assess depressive symptom severity and change over time. Scores on...

The aim of this study was to develop and validate a categorical definition of “no meaningful benefit” from antidepressant treatment by equating percent change in scores on 3 common...